Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma

Investigational New Drugs

Volumn 21, Issue 3, 2003, Pages 341-345

  Drucker, Beverly ^a   Bacik, Jennifer ^a   Ginsberg, Michelle ^a   Marion, Stephanie ^a   Russo, Paul ^a   Mazumdar, Madhu ^a   Motzer, Robert ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Phase II trial; Renal cell carcinoma; ZD1839

Indexed keywords

ALPHA INTERFERON; GEFITINIB; INTERLEUKIN 2; THALIDOMIDE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEPHARITIS; BLOOD TOXICITY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRY EYE; DYSPNEA; EYE DISEASE; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; LIVER TOXICITY; MALE; METASTASIS; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0345714775     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025472712456     Document Type: Article

References (18)

1. Motzer RJ, Bander N, Nanus, D: Renal-cell carcinoma. N Engl J Med 335: 865-867, 1996
2. Korn EL, Arbuck SG, Pluda JM et al.: Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Onc 19(1): 265-272, 2001
3. Lager DJ, Slagel DD, Palechek PL: The expression of epidermal growth factor receptor and transforming growth factor α in renal cell carcinoma. Mod Path 7: 544-548, 1994
4. Wells, A: Molecules in focus EGFR receptor. Int J Biochem Cell Biol 31: 637-642, 1999
5. Perry, JE, Grossman, ME, Tindal, DJ: Epidermal growth factor induces cyclin D1 in human prostate cancer cell line. Prostate 35: 117-124, 1998
6. Noonberg, SB, Benz, CC: Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs 59: 753-767, 2000
7. Sargent EF, Gomella LG, Bellegegrun et al.: Epidermal growth factor receptor gene expression in normal kidney and renal cell carcinoma. J Urol 142: 1364-1368, 1989
8. Ishikawa J, Maeda S, Umezu K: Amplification and overexpression of the epidermal growth factor receptor gene in human renal cell carcinoma. Int J Cancer 45: 1018-1021, 1990
9. Freeman MR, Waschecka R, Chung LWK: Aberrant expression of epidermal growth factor receptor and HER-2 (erB-2) messenger RNAs in human renal cancers. Cancer Res 49: 6221-6225, 1989
10. Moch H, Sauter G, Buchholz N et al.: Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 29: 1255-1259, 1997
11. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, and Woodburn JR: Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 38: 67-73, 1996
12. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results in a phase I trial. JCO 20: 2240-2250, 2002
13. Janne PA, Ostler PA, Lucca J, Fidias P, Skarin AT, Lynch TJ, Johnson BE: ZD1839 ("Iressa") show antitumor activity in patients with recurrent non-small cell lung cancer treated on a compassionate use protocol. Abstract #1274, Annual Meeting of the American Society of Clinical Oncology, 2002
14. Ruckdeschel JC, Simon G, Antonia S, Haura E, Williams C, Wagner H, Rocha Lima C, Ettienne K, Vaughn J, Bepler, G, Lee H: ZD1839 ("Iressa") as a single agent for the treatment of metastatic non-small-cell lung cancer. Abstract #1269, Annual Meeting of the American Society of Clinical Oncology, 2002
15. Soto Parra HJ, Cavina R, Campagnoli E, Zucali P, Ginnani V, Lateri F, Ferrari B, Pedicine V, Roncalli M, Santoro A: ZD1839 (Iressa) in progressive pretreated non-small-cell lung cancer (NSCLC): reults from compassionate use in patients at the Istituto Clinico Humanitas, Rozzano, Milano. Abstract #2657, Annual Meeting of the American Society of Clinical Oncology, 2002
16. Motzer RJ, Mazumdar M, Bacik J et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540, 1999
17. Motzer RJ, Bacik J, Murphy B, Russo P, Mazumdar, M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296
18. Yang JC, Haworth L, Steinberg SM, Rosenberg SA, Novotny W: A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Abstract #15, Annual Meeting of the American Society of Clinical Oncology, 2002